The Company’s most advanced research program is in the cancer field and we are developing novel anticancer molecules, from the chemical class of pyrrolobenzodiazepine dimers that have several distinguishing characteristics from existing anticancer agents. In particular, novel IndUS anticancer compounds are selectively cytotoxic as monotherapy in genetically-resistant cancers with a ‘mutator’ phenotype such as colorectal cancer.
Additional features of novel IndUS anticancer molecules include their preferential cytotoxic activity against tumors that have genetic deficiencies in DNA mismatch repair or homologous recombination pathways. Such mutations are present in several refractory cancers, such as metastatic colorectal, endometrial, ovarian and triple-negative breast cancers.
Novel IndUS anticancer agents show a ‘gain in potency’ due to synthetic lethality in refractory tumors that have deficiencies in genes regulating apoptosis such as p53 or tumor suppression such as PTEN. Furthermore, IndUS novel anticancer agents also show synthetic lethality in colorectal cancer cells that have K-ras mutations, which usually renders colorectal cancer resistant to agents.
Novel IndUS compounds show a great degree of synergy or potentiation with most anticancer agents that are currently available to treat various tumors. The synergies of our molecules with other chemotherapeutic agents (with different mechanism of action), as well has their ability to act as monotherapy in tumors that have traditionally been refractory to therapies, allows additional therapeutic options with novel IndUS anticancer agents for resistant cancers.